All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Artemisinin,Curcumin,Boswellia Serrata
Therapeutic Area: Infections and Infectious Diseases Product Name: ArtemiC
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Malta Enerprises
Deal Size: $3.7 million Upfront Cash: $3.7 million
Deal Type: Funding December 22, 2020
Details:
The Malta facility will create a European manufacturing hub for ArtemiCTM with the ability to scale production to meet expected growing demand following positive clinical trial results.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Artemisinin,Curcumin,Frankincense
Therapeutic Area: Infections and Infectious Diseases Product Name: ArtemiC
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2020
Details:
Interim Results reported to date demonstrate ArtemiCTM has met all primary end points for safety and efficacy, and FDA primary endpoint of sustained clinical recovery of COVID-19 patients.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Eftilagimod Alpha
Therapeutic Area: Infections and Infectious Diseases Product Name: IMP321
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: University Hospital Pilsen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 23, 2020
Details:
Immutep will provide Efti at no cost to the University Hospital Pilsen which will fund the study. Investigator-initiated, placebo controlled and randomised Phase II study will be conducted evaluating eftilagimod alpha in up to 110 COVID-19 patients.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Artemisinin,Curcumin,Frankincense
Therapeutic Area: Infections and Infectious Diseases Product Name: ArtemiC
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2020
Details:
The trial is assessing the safety and efficacy of the natural anti-inflammatory formulation ArtemiCTM, a natural supplement formula based on Artemisinin and Curcumin (along with supporting ingredients Vitamin C and Boswellia serrata) on COVID-19 Patients.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ArtemiC
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 05, 2020
Details:
The double-blind, placebo-controlled Phase II trial will investigate the safety and efficacy of ArtemiC, a natural formulation intended for immune-modulation.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
